Genmab A/S at Barclays Global Healthcare Conference Transcript
Good afternoon, everyone. Thanks for joining. I'm James Gordon, Barclay's European pharma and biotech analyst. And it's my pleasure this afternoon to host a fireside with Genmab and we've got two for the price of one because we've got Anthony Pagano, who is the Chief Financial Officer; and Brad Bailey, who's the Chief Commercial Officer. And we've got a little over 20 minutes, so we're going to discuss some of the exciting pipeline, readouts that come out this year.
Maybe a bit on the longer-term outlook and maybe hopefully when these work, what's the commercial outlook for these products as well, that would be interesting as well.
Questions & Answers
So thanks a lot, both of you for joining. And well, maybe just to start off, so it's a big year of readouts. What is it that's coming out this year? And how excited about them are you? And where should we focus, do you think? What should investors be looking at?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
